METABOLIC DISORDERS IN PATIENTS TREATED WITH SECOND-GENERATION ANTIPSYCHOTICS: AN OPPORTUNITY FOR PHARMACEUTICAL INTERVENTION

METABOLIC DISORDERS IN PATIENTS TREATED WITH SECOND-GENERATION ANTIPSYCHOTICS: AN OPPORTUNITY FOR PHARMACEUTICAL INTERVENTION